After a three-day shutdown, the Senate voted 81-18 on Jan. 22 to pass a three-week continuing resolution to keep the federal government funded through Feb. 8.
E-cigarettes contain a lower number of toxic substances than conventional cigarettes, but their long-term health effects are not yet clear, the National Academies of Sciences, Engineering, and Medicine concluded in a report published Jan. 23.
Gary Reedy has a big turnaround project on his hands.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Foundation Medicine Inc. said the company has entered into a broad partnership with Pfizer Inc.
FDA has approved the supplemental New Drug Application to add overall survival data from the phase III head-to-head ENDEAVOR trial to the Prescribing Information for Kyprolis (carfilzomib).
Novartis said its supplemental Biologics License Application for Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for or relapse after autologous stem cell transplant (ASCT) has been accepted by FDA for Priority Review.
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.
A study published in the Journal of the National Cancer Institute indicates that screening the general population for mutations in specific genes is a more cost-effective way to detect people at risk and prevents more breast and ovarian cancers compared to only screening patients with a personal or family history of these diseases.
An international team, led by researchers at the University of California San Diego School of Medicine, has developed a genetic tool for predicting age of onset of aggressive prostate cancer.
